Shalini Sharp
CIK 1377202 · EVP, Finance · last filed 2026-10-16
Shalini Sharp is an EVP, Finance who has filed 142 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for IAM, was dated Oct 16, 2026. Across all open-market trades the lifetime net is −$18.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions. 54 SEC filings were submitted jointly with AGENUS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RARE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
30 HUDSON ST
JERSEY CITY, NJ 07302
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IAM | Director | — | — | — | $0 | 1 | 2026-10-16 |
| ONC | Director | 9 | $418.57 | $3.8K | $0 | 2 | 2026-06-15 |
| OGN | Director | 2 | $13.87 | $28 | $0 | 6 | 2026-06-15 |
| NBIX | Director | 4,088 | $168.53 | $689.0K | -$156.9K | 9 | 2026-05-29 |
| SEPN | Director | — | $49.51 | — | $0 | 1 | 2025-06-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 8,151 | $184.71 | $1.51M | $0 | 1 | 2024-10-02 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 12,060 | $58.70 | $707.9K | $0 | 5 | 2024-01-23 |
| STRO | Director | — | $10.73 | — | $0 | 5 | 2022-06-08 |
| DTIL | Director | — | $10.05 | — | $0 | 2 | 2021-05-12 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 35,000 | $0.01 | $178 | $0 | 1 | 2021-02-26 |
| RARE | EVP, Finance | 97,812 | $16.33 | $1.60M | -$17.81M | 53 | 2020-10-16 |
| AGEN | Director | 9,280 | $7.47 | $69.3K | -$89.0K | 52 | 2018-06-22 |
Recent Filings
142 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-16 | IAM | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | OGN | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | ONC | Grant (A) | +18,980 | $0 | EDGAR |
| 2026-05-29 | NBIX | Grant (A) | — | $0 | EDGAR |
| 2026-05-21 | NBIX | Exer (M) | +1,659 | $0 | EDGAR |
| 2025-06-20 | SEPN | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | OGN | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | ONC | Grant (A) | +10,985 | $0 | EDGAR |
| 2025-05-22 | NBIX | Mixed | +1,435 | $0 | EDGAR |
| 2024-10-02 | BeOne Medicines Ltd. (BGNE) Delisted | Grant (A) | +8,151 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.